Molecular Cancer Therapeutics: Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
Published Online March 23, 2016; doi: 10.1158/1535-7163.MCT-15-0643 Abstract: The diagnosis, classification, and management of cancer are traditionally dictated by the site of tumor origin, for example, breast or lung, and by specific histologic subtypes of site-of-origin cancers (e.g., non-small cell versus small cell lung cancer). However, with the advent of sequencing technologies allowing for rapid, […]
CollabRx Chief Scientific Officer Smruti Vidwans presents poster describing Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making at Molecular Med Tri-Con 2016
Smruti Vidwans, PhD presented the Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making poster at the 2016 Molecular Medicine Tri Conference in Moscone North Convention Center, San Francisco, CA. Download PDF Publication Reference: Vidwans S. Framework for Genomic Biomarker Actionability and Use in Clinical Decision Making; Poster presented at: Molecular Medicine Tri-Conference […]
CollabRx and Collaborators at Leading Academic Centers Publish Clinical Decision Support Model for Precision Oncology
Publication Establishes Standard Framework to Guide Therapy Selection for Targeted Therapies in Cancer SanFrancisco,CA –November5,2014– CollabRx, Inc. (NASDAQ: CLRX), a leading provider of clinical decision support solutions in oncology, today announced the publication of a clinical decision support model for oncology as an advance publication in the current online edition of the open-access journal Oncoscience.1 […]
The CollabRx Colorectal Targeted Therapy App, and our relationship with CAP (The College of American Pathologists) is briefly described in the latest issue of the British Journal of Healthcare Computing. The article quotes the chief editor of the app, Dr Heinz-Josef Lenz, professor at the Keck School of Medicine, University of Southern California: “The Therapy […]
A team including leading lung cancer researchers, and CollabRx scientists, has just published a novel Lung Cancer Molecular Disease Model in PLoS ONE, a leading peer-reviewed open source journal. (
February, 2012 — CollabRx’s Lung Cancer Targeted Therapy Finder and Dr. Ravi Salga, chief editor and advisor for the Lung Cancer Targeted Therapy Finder, are featured in an article published by the University of Chicago School of Medicine as part of their Comprehensive Cancer Center’s lung cancer program.